Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Jagsonpal Pharmaceuticals targets organic growth at approximately 1.5x the Indian Pharma Market (IPM) growth, aiming for 12%-15% revenue growth. Jagsonpal aims to sustain and accelerate growth momentum, targeting 1.5x the Indian Pharma Market (IPM) growth (currently 6%-9%), implying 12%-15% revenue growth.
From Jagsonpal Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Jagsonpal Pharmaceuticals targets organic growth at approximately 1.5x the Indian Pharma Market (IPM) growth, aiming for 12%-15% revenue growth.
- Volume growth for FY26 was 2% for Jagsonpal, slightly higher than the market's ~1%.
- New product launches contribute around 3.2% to growth, matching or exceeding industry averages.
- Price growth is around 6%-7%, which is higher than the IPM price growth (~4.8%-5%).
- Focus on strong therapeutic areas: Gynaecology (about 50% of business), Orthopedics (~25%), and Dermatology (10%-15%), with growth led mainly by Gynaec and Derma.
- Enhancing MR productivity and training to increase sales efficiency without increasing headcount.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Jagsonpal Pharmaceuticals Limited does not require additional capital for organic growth, as growth is driven by better execution and field force productivity rather than capital-intensive investments.
- Current capital expenditure is focused on maintaining existing operations and organic business growth.
- Any capital deployment of real cash will be primarily for inorganic strategies, such as acquisitions.
- The company has adequate cash (~INR190 crores) and access to bank finance, making it capable of funding acquisitions up to INR400 crores without stressing the balance sheet.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹64 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jagsonpal Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q4 FY26 results?
Jagsonpal Pharmaceuticals targets organic growth at approximately 1.5x the Indian Pharma Market (IPM) growth, aiming for 12%-15% revenue growth. Jagsonpal aims to sustain and accelerate growth momentum, targeting 1.5x the Indian Pharma Market (IPM) growth (currently 6%-9%), implying 12%-15% revenue growth.
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?
Jagsonpal Pharmaceuticals Limited does not require additional capital for organic growth, as growth is driven by better execution and field force productivity rather than capital-intensive investments.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.